Keytruda, Gardasil Boost Merck’s Q2 Revenues, Tightens Annual Guidance
Merck & Co Inc’s (NYSE: MRK) Q2 sales reached $14.60 billion, +28% Y/Y, beating the consensus of $13.87 billion. Excluding the…
Labcorp To Spin Off Its Clinical Trial Business, Posts Mixed Q2 Earnings
Laboratory Corp of America Holdings (NYSE:LH) plans to spin off its unit focused on the clinical development business. Wall Street Journal was the…
Allergan To End Around 3,000 Opioid Lawsuits With Over $2B In Settlement: Report
AbbVie Inc’s (NYSE:ABBV) Allergan unit has agreed to pay more than $2 billion to resolve over 3,000 lawsuits filed…
Recap of Wednesday’s Biotech Catalysts – End of The Day Summary
IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate…
Pfizer/BioNTech Start Phase 2 Trial For COVID-19 Vaccine Against Omicron Subvariant
Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) initiated a randomized, active-controlled, observer-blind Phase 2 study to evaluate the safety, tolerability, and immune response…
Medicenna’s Lead Cancer Program Shows Preliminary Anti-Cancer Activity In Solid Tumor Study
Medicenna Therapeutics Corp (NASDAQ:MDNA) announced new clinical data from the Phase 1/2 ABILITY study of MDNA11. The data provide preliminary evidence…
Cidara Pursues FDA Approval For Bloodstream Infections Candidate
Cidara Therapeutics, Inc. (NASDAQ: CDTX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead asset Rrezafungin for the treatment of candidemia and invasive candidiasis.
Silk Road Medical’s Q2 Margins Hit By Manufacturing Expansion Costs
Silk Road Medical Inc (NASDAQ:SILK) posted Q2 revenue of $33.2 million, an increase of 25% Y/Y, driven primarily by increased…
Recap Of Tuesday’s Biotech Catalysts – End of The Day Summary
European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg…
Woman-Health Focused Stock Agile Therapeutics Is ‘Better Positioned,’ Analyst Says While Upgrading Stock
Maxim Group upgraded Agile Therapeutics Inc (NASDAQ:AGRX) to Buy from Hold with a price target of $1, saying it should be…